Adjuvant pazopanib does not PROTECT against recurrence of high risk initially localised renal cell cancer, but does provide novel insights
Published version
Repository URI
Repository DOI
Change log
Authors
Stewart, GD
Leibovick, BC
Negrier, S
Figlin, RA
Abstract
Improved post-surgical management of the 70% of all renal cell cancer (RCC) patients who present to urological surgeons with initially localised RCC, to prevent subsequent progression, is an area of great need within uro-oncology.
Description
Keywords
Carcinoma, Renal Cell, Humans, Indazoles, Kidney Neoplasms, Neoplasm Recurrence, Local, Nephrectomy, Pyrimidines, Sulfonamides
Journal Title
Journal of Clinical Oncology
Conference Name
Journal ISSN
0732-183X
1527-7755
1527-7755
Volume Title
35
Publisher
American Society of Clinical Oncology
Publisher DOI
Sponsorship
GD Stewart has received educational grants from Pfizer and Intuitive Surgical; consultancy fees from Pfizer, EUSA Pharma and Cambridge Medical Robotics; Travel expenses from Pfizer and Speaker fees from Pfizer. RA Figlin has received research funding from Peloton, BMS, Argos Therapeutics, Exilexis, and Cerulean; consulting fees from Novartis, Pfizer, Nektar, Peloton, Calithera, and Acceleron. S Negrier reports honoraria from Pfizer, Novartis, EUSA Pharma, Ipsen Biotech and Bristol-Myers Squibb. BC Leibovich declares no conflicts of interest.